PedAM
Pediatric Disease Annotations & Medicines
| Disease | crohn disease |
| Phenotype | C0002726|amyloidosis |
| Sentences | 7 |
| PubMedID- 22359896 | The incidence of the association of secondary amyloidosis in patients with crohn's disease has been reported to be 0.5%-8%. |
| PubMedID- 21509909 | Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn's disease. |
| PubMedID- 21175229 | Secondary amyloidosis in a patient with long duration crohn's disease treated with infliximab. |
| PubMedID- 25969738 | One previous study reported that 15 (0.9%) of 1709 patients with crohn's disease were complicated by secondary amyloidosis and only three patients had amyloid deposition in the thyroid (8). |
| PubMedID- 21453891 | Infiximab for treatment of systemic amyloidosis associated with crohn's disease. |
| PubMedID- 21603298 | Secondary amyloidosis is a result of chronic inflammatory disease (crohn's disease, adult or juvenile rheumatoid arthritis, reiter's syndrome, ankylosing spondylitis, familial mediterranean fever, sjögren's syndrome, dermatomyositis, vasculitis, chronic osteomyelitis, tuberculosis, bronchiectasis, cystic fibrosis, systemic lupus erythematosus, and so on) and has a median survival of 4.5 years (10, 11). |
| PubMedID- 24078992 | Effect of infliximab induction therapy on secondary systemic amyloidosis associated with crohn's disease: case report and review of the literature. |
Page: 1